UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC

European journal of cancer (1990), 2015-09, Vol.51, p.S625-S625

2015

Volltextzugriff (PDF)

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse

International journal of infectious diseases, 2010-06, Vol.14 (6), p.e518-e521

2010

Volltextzugriff (PDF)

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Volltextzugriff (PDF)

482P Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort

Annals of oncology, 2023-11, Vol.34, p.S1649-S1650

2023

Volltextzugriff (PDF)

MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S133

2023

Volltextzugriff (PDF)

P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S271

2023

Volltextzugriff (PDF)

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

Annals of oncology, 2017-11, Vol.28 (11), p.2698-2706

2017

Volltextzugriff (PDF)

Evaluating medical oncology outcomes: An Asian lung cancer study

Annals of oncology, 2019-11, Vol.30, p.ix132

2019

Volltextzugriff (PDF)

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma

Annals of oncology, 2023-10, Vol.34, p.S1170-S1170

2023

Volltextzugriff (PDF)

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Annals of oncology, 2022-02, Vol.33 (2), p.181-192

2022

Volltextzugriff (PDF)

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S577-S577

2021

Volltextzugriff (PDF)

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S309-S310

2023

Volltextzugriff (PDF)

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Annals of oncology, 2015-05, Vol.26 (5), p.998-1005

2015

Volltextzugriff (PDF)

Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience

Annals of oncology, 2019-11, Vol.30, p.ix165-ix166

2019

Volltextzugriff (PDF)

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

Annals of oncology, 2022-09, Vol.33, p.S748

2022

Volltextzugriff (PDF)

596P Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial

Annals of oncology, 2023-11, Vol.34, p.S1704

2023

Volltextzugriff (PDF)

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

Annals of oncology, 2023-11, Vol.34, p.S1498

2023

Volltextzugriff (PDF)

371P Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis

Annals of oncology, 2020-11, Vol.31, p.S1384-S1384

2020

Volltextzugriff (PDF)

372P Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study

Annals of oncology, 2020-11, Vol.31, p.S1384-S1384

2020

Volltextzugriff (PDF)

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

Annals of oncology, 2013-09, Vol.24 (9), p.2364-2370

2013

Volltextzugriff (PDF)

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Annals of oncology, 2023-10, Vol.34, p.S776-S776

2023

Volltextzugriff (PDF)

393MO Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer

Annals of oncology, 2022-11, Vol.33, p.S1566-S1567

2022

Volltextzugriff (PDF)

992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)

Annals of oncology, 2022-09, Vol.33, p.S1007

2022

Volltextzugriff (PDF)

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

ESMO open, 2024-03, Vol.9, p.102681, Article 102681

2024

Volltextzugriff (PDF)

400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study

Annals of oncology, 2020-11, Vol.31, p.S1399-S1399

2020

Volltextzugriff (PDF)

1 – 25 von 106

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Industrial And Engineering Chemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(102)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

3082 The highly selective c-Met inhibitor tepotinib in combination with gefitinib is active in Asian patients with c-Met-positive EGFR mutant NSCLC

Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

482P Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort

MA10.03 A Cost-Effectiveness Analysis of Actionable Genomic Alteration (AGA) Testing Strategies in Non-Small Cell Lung Cancer (NSCLC)

P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)

Evaluating medical oncology outcomes: An Asian lung cancer study

2282P Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients

P2.05-05 Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience

458MO Efficacy of durvalumab (Durva) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic (met) cancers (Ca) (MEDIPAC)

596P Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial

82P NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies

371P Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis

372P Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

393MO Evaluating medical oncology outcomes (EMOO) in Asia study: Molecular testing, treatment patterns and outcome of patients with stage IV non-squamous non-small cell lung cancer

992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)

102TiP A phase III randomised controlled trial of zongertinib (BI 1810631) compared with standard of care (SoC) in patients (pts) with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain (TKD) mutations: Beamion LUNG-2

400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study

Aktive Filter

Suchergebnisse filtern